Form 4: Dyne Therapeutics Director Jason P. Rhodes Sells Shares in Multiple Transactions

Director Jason P. Rhodes of Dyne Therapeutics sold a total of 782 shares of common stock across multiple transactions on November 14, 2024, at an average price of $33.1.

Summary

• Jason P. Rhodes, a director at Dyne Therapeutics, executed multiple sales of the company's common stock on November 14, 2024.
• The sales were conducted at a weighted average price of $33.1 per share.
• A total of 782 shares were sold across these transactions.
• The sales were made through various investment funds associated with Atlas Venture, where Mr. Rhodes is a member of the general partner.
• Mr. Rhodes disclaims beneficial ownership of the shares held by these funds, except to the extent of his pecuniary interest.

Sentiment

Score: 5

Explanation: The document is a routine disclosure of insider trading activity. It doesn't indicate any positive or negative sentiment about the company's performance or future prospects.

Industry Context

This is a standard SEC Form 4 filing, which is required when company insiders trade shares. It provides transparency into the trading activities of company directors and officers.

Comparison to Industry Standards

• Form 4 filings are a common occurrence for publicly traded companies, and this filing is consistent with standard practices.
• The transactions are relatively small in volume compared to the total shares held by the associated funds, suggesting routine portfolio management rather than a significant change in outlook.

Stakeholder Impact

• The stock sales by a director may have a minor impact on shareholder sentiment, but the volume is relatively small.

Key Dates

Keywords

Dyne Therapeutics, Jason P. Rhodes, stock sale, insider trading, Atlas Venture, common stock, share transaction